Life Science Investment Community Survey: Assessing COVID-19 Disclosure Expectations and Implications

As we move past the initial panic and any off-cycle business impact announcements related to COVID-19, companies are at a critical inflection point as they prepare for first quarter earnings and adjust full year investor relations planning. With a somewhat clearer understanding of the near-term business impact of the virus juxtaposed with the uncertainty around timelines and longer-term consequences, companies are in a difficult position of trying to maintain transparency with investors looking for directional updates around key value drivers without much of the information currently in hand.

With investor conferences going virtual and non-deal roadshows halted, what does a proper investor engagement strategy look like in this COVID-19 era? Further, how should management teams communicate to the Street with no understanding of timelines and full economic impact from the virus?

To help assess current capital markets expectations and provide more context around COVID-19 impact and best practices, FTI surveyed select members of the Life Sciences investment community to ascertain insights.

Related Articles

January 14, 2022

FTI Consulting News Bytes – 14th January 2022

Welcome to FTI Consulting News Bytes – a roundup of top tech stories of the week from FTI Consulting’s TMT (Telecom,...

January 13, 2022

FTI Consulting Public Affairs Snapshot: To CBDC or not to CBDC?

The Mesopotamian shekel is often cited as the first form of money, initially representing a specific weight of barley, a...

January 13, 2022

ESG+ Newsletter – 13th January 2022

Your weekly updates on ESG and more Greetings from 2022! Our first ESG+ Newsletter of the year starts off with a review ...